Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

The first quarter of 2026 brought regulatory approvals, late-stage psychedelic data, and increased use of at-home neuromodulation and artificial intelligence–supported mental health tools that reflected rapid change across psychiatry. 

 decisions expanded treatment options for acute bipolar I disorder, schizophrenia, and 

, alongside progress toward a potential new nonstimulant therapy for ADHD.

Q1 developments emphasized faster-acting therapies, at-home treatment delivery, and technology-driven care innovation. This recap spotlights 7 psychiatry headlines in Q1.

FDA Updates in Psychiatry: New Approvals 

FDA Approves Milsaperidone for Acute Bipolar I Disorder, Schizophrenia

The FDA approved Vanda Pharmaceuticals’ milsaperidone (BYSANTI) for the treatment of acute bipolar I disorder and schizophrenia, expanding pharmacologic options for patients experiencing acute psychiatric episodes. Clinical data supporting approval demonstrated significant symptom improvement across key measures, with tolerability findings consistent with expectations for second-generation antipsychotics. The approval adds another mechanism for clinicians managing acute mood and psychotic symptoms.

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

The FDA approved Neurolief’s ProlivRx, the first at-home neuromodulation device for MDD. The decision represents a shift toward decentralized treatment models, allowing patients to receive neuromodulation therapy outside clinic settings. Investigators highlighted potential benefits for access, adherence, and reduced logistical burden, particularly for individuals unable to attend frequent in-office sessions.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

The FDA accepted the new drug application for centanafadine for adult and pediatric ADHD and granted priority review. Centanafadine, developed by Otsuka, is a triple reuptake inhibitor targeting norepinephrine, dopamine, and serotonin, representing a potential nonstimulant option. The FDA assigned centanafadine a Prescription Drug User Fee Act (PDUFA) target action date of July 24, 2026.

Promising Phase 2 & Phase 3 Data: Rapid-Acting Psychedelic Therapies 

COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRD

The second phase 3 trial of Compass Pathways’ COMP360 psilocybin met its primary endpoint in treatment-resistant depression (TRD), reinforcing prior late-stage findings. Investigators reported that two 25 mg COMP360 doses administered 3 weeks apart produced a statistically significant reduction in depressive symptom severity at week 6 compared with a 1 mg dose control. The findings support the potential role of psychedelic-assisted therapy in patients with limited treatment response.

COMP360 Psilocybin Shows Rapid, Durable Effect in TRD, With Steve Levine, MD

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

A Phase 2b trial evaluating inhaled GH001 demonstrated rapid and clinically meaningful antidepressant effects following a single-day individualized dosing session. Michael E. Thase, MD, of the University of Pennsylvania, highlighted the rapid onset and potential scalability of a single-session psychedelic-based intervention compared with multi-session treatment models. The study showed that GH001 could improve depression severity within 1 week.

Intravenous DMT (SPL026) Demonstrates Significant MDD Reduction in Phase 2a Trial

Phase 2a data for SPL026, an intravenous formulation of dimethyltryptamine (DMT), showed significant reductions in depressive symptoms among patients with MDD. The therapy was associated with a rapid onset of action, adding to the growing body of evidence supporting short-duration psychedelic interventions.

SPL026 is a short-acting serotonergic psychedelic that acts primarily as a 5-HT2A receptor agonist. Unlike psilocybin, which can produce psychoactive effects lasting 4 to 6 hours, intravenous DMT has a shorter duration of acute subjective effects, often under 30 minutes.

Helus Pharma stated they will not be advancing the intravenous formulation in its current form but are using the trial insights to develop HLP004, a proprietary novel serotonergic agonist under investigation for generalized anxiety disorder (GAD).

Your Patient's New Therapist Is an AI. Now What?

Increasing patient use of generative artificial intelligence tools for mental health support sparked discussion around clinical oversight and safety. Experts noted that patients are turning to AI for therapy-like conversations, raising questions about accuracy, crisis management, and appropriate clinician guidance. Although AI may improve access and reduce stigma, clinicians emphasized that these tools should complement, not replace, professional mental health care, particularly for complex or high-risk cases.

Articles

The first quarter of 2026 underscored accelerating diversification in psychiatric therapeutics and care delivery, spanning novel antipsychotic options, decentralized neuromodulation, and rapid-acting psychedelic platforms. Regulatory actions included approval of milsaperidone for acute bipolar I disorder and schizophrenia, authorization of an at-home neuromodulation device for MDD, and priority review of a triple reuptake inhibitor as a potential nonstimulant ADHD treatment. Late-stage and mid-stage trials supported short-duration psychedelic interventions with rapid antidepressant effects, while generative AI’s growing patient adoption intensified scrutiny around safety, oversight, and appropriate clinical integration.

FDA approvals, at-home neuromodulation, phase 3 psychedelic data, and rising AI therapy use impacted the psychiatry field in the first quarter of 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Q1 2026 Recap: Psychiatry News and Updates

Narendra Singh, MD, is an assistant professor at Mercer University Atlanta Campus and the director of clinical research at NSC Cardiology.

Self-Administered Etripamil for PSVT Has Minimal Blood Pressure, Heart Rate Effects, With Narendra Singh, MD

Although calcium channel blockers (CBBs) typically carry a risk of hypotension, the recently approved, self-administered nasal spray etripamil results in minimal blood pressure reduction when treating paroxysmal supraventricular tachycardia (PSVT).

American College of Cardiology (ACC) Scientific Sessions 2026

 in New Orleans, Louisiana, by James Ip, MD, a professor of medicine and the director of cardiac pacing and implantable devices at Weill Cornell Medicine. At the conference, the 

 editorial team spoke with Narendra Singh, MD, assistant professor at Mercer University Atlanta Campus, director of clinical research at NSC Cardiology, and co-author of the study, to learn more.

“This provides a huge amount of reassurance that we’re not seeing a big drop in blood pressure, and we’re not seeing a big drop in heart rate,” Singh told 

 in an exclusive interview. “Hopefully, for both the patients and for the clinicians, this will improve the comfort level of offering and using this drug.”

Etripamil nasal spray received approval from the US Food and Drug Administration (FDA) in December of 2025, indicating it for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adult patients. This approval was based in large part on the NODE clinical trial program, which included data from >1800 participants with >2000 episodes of PSVT.

The present study analyzed NODE-301 parts 1-3 to assess etripamil’s effects on blood pressure and symptoms of hypotension. Singh and colleagues examined the mean heart rate and blood pressure change from baseline for 30-45 minutes post-test dose of etripamil 70mg in enrolled patients. A descriptive analysis was also conducted to investigate symptoms of potential hypotension or syncope treatment-emergent adverse events across the trials conducted during PSVT episodes self-treated out of the clinic.

Ultimately, the team reported minimal changes from baseline in either heart rate or blood pressure following etripamil use. The mean change in systolic blood pressure was 1.8 mmHg (standard deviation [SD], 11.2) over 30 minutes after a single dose of etripamil (

 = 440) and 0.0 mmHg (SD, 12) over 45 minutes for repeat doses (

 = 714). Among the 1610 patients enrolled in all 3 parts of NODE-301, treatment-emergent adverse events of hypotension and syncope within 24 hours were 0.4% and 0.1%, respectively. Medical intervention was not required in any event.

With these data, Singh and colleagues determined that etripamil nasal spray does not share the common hypotension risk of other CCBs, thereby supporting its safe self-administration for PSVT treatment.

“Within the clinical trial itself, we actually had given a second dose 10 minutes later and still shown that there isn’t a big variation in terms of blood pressure and heart rate,” Singh said. “We can provide that reassurance to patients, but we still caution them that if they feel lightheaded or dizzy, we want them to check their blood pressure and heart rate, because in the real world we are going to see some variation.”

Editors’ Note: Singh reports disclosures with Amgen, AstraZeneca, Bayer, Cleveland Clinic, Eli Lilly, Janssen, and others.

Ip J, Noseworthy P, Rafii F, et al. Minimal Blood Pressure Effects of Intranasal Etripamil in Trials for Paroxysmal Supraventricular Tachycardia. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, LA. March 28-30, 2026.

Milestone Pharmaceuticals. Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT). December 12, 2025. Accessed April 8, 2026. 

https://investors.milestonepharma.com/news-releases/news-release-details/milestone-receives-fda-approval-cardamysttm-etripamil-first-and/

Videos

Singh discusses his analysis of all 3 parts of the NODE-301 phase 3 trial, investigating the recently approved CBB’s potential risk of hypotension.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

Self-Administered Etripamil for PSVT Has Minimal Blood Pressure, Heart Rate Effects, With Nerendra Singh, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The first quarter of 2026 delivered a steady stream of meaningful updates in gastroenterology, with advances spanning irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and real-world insights into treatment access and durability. Across clinical trials and observational research, the field continues to move toward more personalized, evidence-driven care while also grappling with persistent gaps in access and affordability.

Much of the momentum centered on IBD, where long-term extension data and real-world studies reinforced the durability and effectiveness of newer agents targeting IL-23 and JAK pathways. At the same time, head-to-head and sequencing data are beginning to more directly inform clinical decision-making, particularly in patients with prior biologic exposure. Parallel progress in IBS, including emerging microbiome-based therapies, signals growing innovation beyond traditional treatment paradigms.

Beyond therapeutics, the quarter also highlighted the broader patient experience, with new data underscoring the disproportionate financial and access-related challenges faced by younger adults with IBD.

Here’s a look at the key gastroenterology developments from Q1 2026.

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

On January 8, 2026, EnteroBiotix Limited announced positive final results from TrIuMPH, a phase 2a clinical trial evaluating EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, in patients with IBS-C or IBS-D. In the 122-patient TrIuMPH study, EBX-102-02 demonstrated clinically meaningful improvements in the IBS symptom severity score versus placebo, with clear separation from placebo observed as early as week 1 and sustained throughout the 6-week follow up period in both the IBS-C and IBS-D cohorts.

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Recent research from the Crohn’s & Colitis Foundation sheds light on disproportionate healthcare access and financial burdens faced by young adults with IBD, highlighting greater levels of healthcare access challenges and financial distress among young adults versus adult and pediatric patients with the disease.

Bridging the Insurance Gap in Transition-Age IBD Care, With Laura Wingate

LUCENT: Durable UC Control With Mirikizumab Through 4 Years, With Fernando Magro, MD, PhD

Long-term findings from the LUCENT clinical program continue to strengthen the case for mirikizumab (Omvoh) as a potential disease-modifying therapy in moderately-to-severely active UC. Data presented at the 21st Congress of ECCO demonstrate the p19-directed interleukin (IL)-23 monoclonal antibody’s sustained efficacy and safety through 212 weeks of continuous treatment across the LUCENT-1 (induction), LUCENT-2 (maintenance), and LUCENT-3 (open-label extension) trials.

From Induction to Year 4: Mirikizumab’s Lasting Impact in Ulcerative Colitis

How Head-to-Head SEQUENCE Data Shape Crohn’s Disease Treatment Decisions, With Raja Atreya, MD

New long-term data from the SEQUENCE program, presented at the the 21st Congress of ECCO, continue to reinforce the clinical impact of risankizumab (Skyrizi) in moderate-to-severe Crohn’s disease, particularly among patients with prior anti-TNF failure. In discussing the findings, Raja Atreya, MD, head of the IBD Center at University Hospital of Erlangen, characterized SEQUENCE as a “landmark” trial and emphasized that its design and durability data are directly shaping real-world decision-making.

Sustained Remission in Hard-to-Treat Crohn’s: Insights From SEQUENCE

PROFUNDUS: Real-World Outcomes With Upadacitinib in Ulcerative Colitis, With Remo Panaccione, MD

New interim data from the ongoing PROFUNDUS study, presented at the 21st Congress of ECCO, provide important real-world insight into the effectiveness and safety of upadacitinib (Rinvoq) in patients with moderate-to-severe UC. While randomized controlled trials established the drug’s efficacy under tightly controlled conditions, the PROFUNDUS findings help clarify how those results translate into everyday clinical practice.

Real-World Upadacitinib Results in Ulcerative Colitis

3-Year Efficacy, Safety of Mirikizumab in Crohn’s Disease: Insights From VIVID-2, With Edward Barnes, MD, MPH

Long-term durability remains one of the central questions in the management of moderate-to-severe Crohn’s disease. While many advanced therapies demonstrate strong induction and shorter-term maintenance data, clinicians often grapple with whether those benefits persist and whether safety signals emerge with longer exposure.

New 3-year results from the ongoing VIVID-2 extension study offer important insight into the sustained efficacy and safety of mirikizumab, a selective IL-23p19 monoclonal antibody that earned US Food and Drug Administration approval for Crohn’s in January 2025 based on positive results from the phase 3 VIVID-1 study in adults with moderately to severely active Crohn’s who had an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, and/or biologics.

Long-Term Crohn’s Disease Management: Inside the VIVID-2 Mirikizumab Data

AFFIRM: Risankizumab (Skyrizi) Subcutaneous Induction Achieves Primary Endpoints in Crohn’s Disease

On March 2, 2026, AbbVie announced positive topline results from the phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (Skyrizi) subcutaneous (SC) induction treatment versus placebo in adult patients with moderately to severely active Crohn's disease (CD). Study findings showed significantly greater proportions of patients treated with risankizumab SC induction achieved the co-primary endpoints of Crohn's Disease Activity Index (CDAI) clinical remission and endoscopic response at week 12 compared to placebo. Of note, among patients with clinical response after 12 weeks of risankizumab SC induction treatment followed by 12 weeks of maintenance, 67% achieved CDAI clinical remission at week 24 and 57% achieved endoscopic response at week 24.

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

Q1 2026 GI updates include advances in IBD and IBS therapies, long-term data, and new insights into access challenges for younger patients.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Q1 2026 Recap: Gastroenterology News and Updates

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

An expert panel published 12 new evidence-based recommendations to support clinicians’ decision-making of anticoagulant prophylaxis in pediatric patients at risk for venous thromboembolism (VTE).

The guidelines were released on April 8, 2026, in 

 from the American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH), and address an unmet need in this pediatric population.

“This patient group is often among the most vulnerable and medically complex we treat, and clinicians have long lacked clear guidance on how to best care for them,” said ASH President Robert Negrin, MD, in a statement. “These guidelines mark an important step in establishing clinical consensus to improve care and outcomes for children facing serious, life-threatening conditions. The Society is pleased to have collaborated with ISTH on this urgently needed project.”

VTE is caused by venous thrombosis, a complete or incomplete obstruction of blood vessels. This impairment of venous return is crucial for determining cardiac output and maintaining blood pressure. The most commonly reported presentations of VTE include deep vein thrombosis (DVT) and pulmonary embolism (PE).

The condition is linked to hospitalizations, with >90% if pediatric cases triggered by underlying risk factors, most notably central venous catheters (CVCs), malignancy, and chronic illness. Due to an increased survival rate for critically ill children, increased awareness, and more sensitive diagnostic tools, the incidence has significantly increased. In children who are hospitalized, the rate has elevated to 100–1000 times, reaching ≥58 per 10,000 admissions.

The use of anticoagulant prophylaxis in VTE has been more commonly examined in adults, leading to a reliance on this data despite pediatric differences in hemostasis and bleeding risks. The challenges of understanding when to use anticoagulant prophylaxis in pediatric patients include balancing thrombotic risk against bleeding, managing needle phobia with injections, and uncertainty in identifying which patients truly benefit.

To examine anticoagulant prophylaxis in pediatric VTE, ASH and ISTH assembled a panel consisting of a multidisciplinary group of experts, with guidelines intended to support patients and health care professionals in decisions about anticoagulant prophylaxis for pediatric VTE prevention.

For pediatric patients with solid cancer, trauma, or critically ill, the panel issued conditional recommendations suggesting no anticoagulant prophylaxis. For pediatric patients with antiphospholipid antibody syndrome, or those on long-term total parenteral nutrition, the panel issued conditional recommendations suggesting the use of anticoagulant prophylaxis. Other pediatric subgroups addressed included patients with acute lymphoblastic leukemia or lymphoma, surgical and hospitalized patients, and those with a central venous access device.

Additionally, the guidelines encourage institutions to develop protocols for managing interruptions to therapy, particularly for those undergoing lumbar puncture or spinal anesthesia procedures. They also highlight the need for further research to develop VTE risk assessment models for this population and to evaluate the safety and efficacy of prophylaxis across different pediatric subgroups.

“Prior to the development of these clinical guidelines, much of the data we referenced for VTE prevention in pediatric patients was extrapolated from adults, whose risk profiles are generally less varied and complex,” said Marisol Betensky, MD, MPH, associate professor of pediatrics in the division of hematology at Johns Hopkins University School of Medicine, pediatric hematologist in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute, and co-chair of the guidelines. “These guidelines provide physicians with an evidence-based framework to make decisions about VTE prophylaxis for children.”

Betensky M, Azzam M, Bercovitz RS, et al. ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism. 

https://doi.org/10.1182/bloodadvances.2025019415

ASH and ISTH publish new clinical practice guidelines on anticoagulant prophylaxis in pediatric patients at risk of blood clots. EurekAlert! Published April 8, 2026. Accessed April 8, 2026. 

https://www.eurekalert.org/news-releases/1122908

Li HY, Wang J, Wang T, Wang HS. Management of venous thromboembolism in pediatric patients: Quality assessment of clinical practice guidelines and variations in recommendations. Science Direct.‌ 

https://www.sciencedirect.com/science/article/pii/S0049384823001226

Obeagu EI. Pediatric thrombosis: Risk factors, diagnosis, and prevention strategies. 

https://doi.org/10.1097/md.0000000000043370

New ASH–ISTH guidance delivers 12 evidence-based recommendations for anticoagulant prophylaxis in pediatric patients at VTE risk, addressing long-standing reliance on adult-derived data despite pediatric hemostatic differences. Pediatric VTE is predominantly hospital-associated and usually precipitated by underlying risk factors such as central venous catheters, malignancy, and chronic illness, with markedly rising incidence among hospitalized children. Recommendations are largely conditional and emphasize individualized risk–benefit balancing, operational planning for peri-procedural interruptions, and urgent research needs for pediatric-specific risk models and subgroup efficacy/safety data.

Hematology

Breaking News

12 New Recommendations For Anticoagulant Prophylaxis in Pediatric Patients at Risk for Venous Thromboembolism

Michelle O'Donoghue, MD, is the McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School

Gray Areas and Controversies in the 2025 ACS Guidelines, With Michelle O’Donoghue, MD, MPH

Although the 2025 guidelines for the management of 

 are exhaustive and relatively all-inclusive, recent research has highlighted gray areas, controversies, and potential points of confusion for clinicians.

 in New Orleans, Louisiana, the editorial team at 

 spoke with Michelle O’Donoghue, MD, MPH, the McGillycuddy-Logue Endowed Chair in Cardiology, associate professor at Harvard Medical School, and member of the original guideline authors, to discuss the presentations she chaired regarding the ACS guidelines.

“The body of knowledge that we have to support our recommendations continues to evolve at a pretty dizzying pace, so it’s almost hard for guideline writers to keep up,” O’Donoghue told 

 in an exclusive interview. “Part of what we’d like to discuss during this session is the subsequent evidence that has come to light post-completion of the guidelines and how that might shape our thinking.”

The guidelines were initially drafted following a comprehensive literature search, which was conducted from July 2023 to April 2024. The process included clinical studies, systematic reviews, meta-analyses, and other evidence involving human participants. However, O’Donoghue notes that the constant and rapid evolution of research in both ACS and more broadly in cardiology means that any guidelines will be incomplete after publication.

O’Donoghue also indicated several gray areas within the guidelines in terms of treatment, particularly regarding beta blockers. These decrease myocardial oxygen demand via a reduction in the heart rate, blood pressure, and myocardial contractility. Although beta blockers have a well-established clinical benefit in patients with left ventricular ejection fraction (LVEF) <40% and stabilized heart failure, no adequately powered trials have examined the benefit of beta blockers during hospitalization for patients with non-ST-segment elevation ACS (NSTE-ACS).

“Beta blocker therapy is one of the areas where there continues to be additional clinical trials that have been released since the finalization of the 2025 document,” O’Donoghue said. “I think that’s going to be an interesting discussion – how do we start all patients with an ACS on beta blockers at the beginning, and do we continue it post-discharge? Is it only going to be a select group of patients that we continue beta blocker therapy? Is there any risk from beta blocker discontinuation?”

Ultimately, O’Donoghue suggests that documents such as the ACS guidelines inevitably need to be transformed into a “living document” – in other words, a version that is open to regular updates following the completion of new trials or the release of new suggestions.

“There is a plan to make it more of a living document, and some of that might be in the form of more annual – or at least regular – updates rather than completely redrafting the whole document,” O’Donoghue said. “We need more focused updates, since we certainly went too long with a 10-year gap between the last version of the ACS guidelines and this new release.”

Editors’ Note: O’Donoghue reports disclosures with Amgen, Novartis, Janssen, AstraZeneca, GlaxoSmithKline, Intarcia, and others.

Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. 

O’Donoghue addresses the inherent limitations in the ACS guidelines, from the constant influx of further research to the ambiguity of certain treatment recommendations.

Structural Heart Disease

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Lunsekimig Meets End Points in Asthma and CRSwNP, Misses in Atopic Dermatitis

Q1 2026 hepatology highlights include advances in MASH, hepatitis B, gene editing for AATD, and the first approved therapy for pruritus in PBC.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Alpha-1 antitrypsin deficiency

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Q1 2026 Recap: Hepatology News and Updates

2-year results from phase 3 APPLAUSE-IgAN demonstrate slower eGFR decline, reduced composite kidney failure, and proteinuria in IgAN patients treated with iptacopan. 


IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

APPLAUSE-IgAN: Iptacopan (Fabhalta) Exhibits 49.3% Slower eGFR Decline in IgAN Patients Than Placebo

Panelists discuss the signs, symptoms, diagnostic delays, and classification of obstructive hypertrophic cardiomyopathy, including how it differs from other forms and its implications for clinical management.

Video Series

Recognizing and Classifying Obstructive Hypertrophic Cardiomyopathy

Panelists discuss the challenges and gaps in diagnosing hypertrophic cardiomyopathy, including variability in clinical practice, underdiagnosis, and opportunities to improve detection.

Diagnosing Hypertrophic Cardiomyopathy: Challenges and Gaps in Clinical Practice

Learn when to switch to IV iron, which formulations need fewer infusions, and how to manage rare reactions, MRI issues, and hypophosphatemia.

Intravenous Iron — When to Escalate, Formulation Choice, and Safety Considerations 

The Q1 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Q1 2026 Recap: Pulmonology News and Updates

March 2026 saw new data from pivotal clinical trials and new expert conversations on HCPLive.

5 Pulmonology Headlines You Missed in March 2026

Michael H. Gold, MD, is the founder and medical director of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center.

In this Q&A interview at AAD 2026, Gold highlights various tips and strategies for healing scars among patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Scar Management Strategies Tailored to Patients of Color, With Michael H. Gold, MD

Andrew Yockey, PhD, assistant professor at the University of Mississippi.

Survey data show a nearly 40% drop in adolescent depressive episodes post-pandemic, though clinicians should remain vigilant for disparities and unmet care needs, Yockey says.

Latest News

Q1 2026 Recap: Psychiatry News and Updates

Self-Administered Etripamil for PSVT Has Minimal Blood Pressure, Heart Rate Effects, With Nerendra Singh, MD

Q1 2026 Recap: Gastroenterology News and Updates

12 New Recommendations For Anticoagulant Prophylaxis in Pediatric Patients at Risk for Venous Thromboembolism

Gray Areas and Controversies in the 2025 ACS Guidelines, With Michelle O’Donoghue, MD, MPH